German gov’t deals blow to Sanofi-Aventis’ Acomplia

Share this article:
Sanofi-Aventis said it intends to contest in court the decision by the German health ministry to classify anti-obesity drug Acomplia as a non-reimbursable drug. The ministry recommendation was published in the Official Journal of the Government, prompting an immediate response by the drug maker. “Sanofi-Aventis considers the proposed reimbursement classification of Acomplia as unjustified given the profile of the drug,” the firm said in a statement. Sanofi has argued that, since it helps lower a person's risk for developing diabetes and heart disease in addition to helping with weight loss, rimonabant should be covered under the state health insurance program.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.